Imbalance of Circulating Follicular Regulatory and Follicular Helper T Cell Subpopulations Is Associated with Disease Progression and Serum CYFRA 21-1 Levels in Patients with Non-small Cell Lung Cancer

Objective This study aimed to investigate the changes of follicular helper T(TFH)and follicular regulatory T(TFR)cell subpopulations in patients with non-small cell lung cancer(NSCLC)and their significance.Methods Peripheral blood was collected from 58 NSCLC patients at different stages and 38 healthy controls.Flow cytometry was used to detect TFH cell subpopulation based on programmed death 1(PD-1)and inducible co-stimulator(ICOS),and TFR cell subpopulation based on cluster determinant 45RA(CD45RA)and forkhead box protein P3(FoxP3).The levels of interleukin-10(IL-10),interleukin-17a(IL-17a),interleukin-21(IL-21),and transforming growth factor-β(TGF-β)in the plasma were measured,and changes in circulating B cell subsets and plasma IgG levels were also analyzed.The correlation between serum cytokeratin fragment antigen 21-1(CYFRA 21-1)levels and TFH,TFR,or B cell subpopulations was further explored.Results The TFR/TFH ratio increased significantly in NSCLC patients.The CD45RA^(+)FoxP3^(int) TFR subsets were increased,with their proportions increasing in stages Ⅱ to Ⅲ and decreasing in stage IV.PD-1^(+)ICOS+TFH cells showed a downward trend with increasing stages.Plasma IL-21 and TGF-β concentrations were increased in NSCLC patients compared with healthy controls.Plasmablasts,plasma IgG levels,and CD45RA^(+)FoxP3^(int) TFR cells showed similar trends.TFH numbers and plasmablasts were positively correlated with CYFRA 21-1 in stages Ⅰ-Ⅲ and negatively correlated with CYFRA 21-1 in stage IV.Conclusion Circulating TFH and TFR cell subpopulations and plasmablasts dynamically change in different stages of NSCLC,which is associated with serum CYFRA 21-1 levels and reflects disease progression.

Clinical Effects of the Follicular Phase Long Regimen and Luteal Phase Long Regimen on Ovulation Induction in IVF-ET Treatment: A Meta-Analysis

Objective:To systematically evaluate the clinical effects of the follicular phase long regimen and the luteal phase long regimen on ovulation induction in IVF-ET treatment.Methods:Databases including PubMed,Embase,Cochrane Library,CNKI,Chinese Biomedical Literature(CBM),VIP,Wanfang,and others were searched up to January 2021.Clinical studies on ovulation induction using the follicular phase long regimen and luteal phase long regimen in IVF-ET treatment were identified.Literature screening,data extraction,and quality evaluation were conducted based on inclusion and exclusion criteria.Meta-analysis was performed using RevMan 5.3 software.Results:After screening,a total of 11 studies were included,comprising 21,544 patients:9,974 in the follicular phase long regimen group and 11,570 in the luteal phase long regimen group.The meta-analysis results were as follows:(1)The number of Gn days and the total amount of Gn in the follicular phase long regimen were higher than those in the luteal phase long regimen(P<0.05);(2)The number of eggs obtained in the follicular phase long regimen was higher than that in the luteal phase long regimen(P<0.05).There were no significant differences in the rate of embryo optimization and cycle cancellation between the two groups(P>0.05);(3)The embryo implantation rate and clinical pregnancy rate in the follicular phase long regimen were higher than those in the luteal phase long regimen(P<0.05),while the abortion rate in the follicular phase long regimen was lower than that in the luteal phase long regimen(P<0.05).Conclusion:Compared to the luteal phase long regimen,the follicular phase long regimen involves more Gn days and a higher total amount of Gn.The optimal embryo rate and cycle cancellation rate were similar between the regimens,but the follicular phase long regimen resulted in more eggs,significantly improved the implantation and clinical pregnancy rates,and reduced the abortion rate.However,these conclusions require further validation through more multicenter,large-sample RCT studies.

Multi‑omics analysis reveals gut microbiota‑ovary axis contributed to the follicular development difference between Meishan and Landrace×Yorkshire sows

Background The mechanism by which Meishan(MS)sows are superior to white crossbred sows in ovarian follicle development remains unclear.Given gut microbiota could regulate female ovarian function and reproductive capacity,this study aimed to determine the role of gut microbiota-ovary axis on follicular development in sows.Methods We compared the ovarian follicular development,gut microbiota,plasma metabolome,and follicular fluid metabolome between MS and Landrace×Yorkshire(L×Y)sows.A H_(2)O_(2)-induced cell apoptosis model was used to evaluate the effects of multi-omics identified metabolites on the apoptosis of porcine ovarian granulosa cells in vitro.Results Compared with L×Y sows,MS sows have greater ovary weight and improved follicular development,including the greater counts of large follicles of diameter≥5 mm,secondary follicles,and antral follicles,but lesser atretic follicles.The ovarian granulosa cells in MS sows had alleviated apoptosis,which was indicated by the increased BCL-2,decreased caspases-3,and decreased cleaved caspases-3 than in L×Y sows.The ovarian follicular fluid of MS sows had higher concentrations of estradiol,progesterone,follicle-stimulating hormone,luteinizing hormone,and insulin like growth factor 1 than L×Y sows.Gut microbiota of MS sows formed a distinct cluster and had improved alpha diversity,including increased Shannon and decreased Simpson than those of L×Y sows.Corresponding to the enhanced function of carbohydrate metabolism and elevated short-chain fatty acids(SCFAs)in feces,the differential metabolites in plasma between MS and L×Y sows are also mainly enriched in pathways of fatty acid metabolism.There were significant correlations among SCFAs with follicular development,ovarian granulosa cells apoptosis,and follicular fluid hormones,respectively.Noteworthily,compared with L×Y sows,MS sows had higher follicular fluid SCFAs concentrations which could ameliorate H_(2)O_(2)-induced porcine granulosa cells apoptosis in vitro.Conclusion MS sows have more secondary and antral follicles,but fewer atretic follicles and apoptotic ovarian granulosa cells,as well as harbored a distinctive gut microbiota than L×Y sows.Gut microbiota may participate in regulating ovarian follicular development via SCFAs affecting granulosa cells apoptosis in sows.

Clinical features and prognostic factors in 49 patients with follicular lymphoma at a single center:A retrospective analysis

BACKGROUND Follicular lymphoma(FL)is a type of B-cell lymphoma that originates at the germinal center and has a low malignancy rate.FL has become the most common inert lymphoma in Europe and America but has a relatively low incidence in Asia.AIM To explore the clinical features,curative effects,and prognostic factors of FL.METHODS Completed medical records of 49 patients with FL who were admitted to the Ningbo First Hospital from June 2010 to June 2021 were examined.These patients were definitively diagnosed by pathological biopsy or immunohistochemical staining.The diagnostic criteria were based on the 2008 World Health Organization classification of lymphomas.Ann Arbor staging was performed according to the imaging and bone marrow examination results.Risk stratification of all patients was performed based on the International Prognostic Index(IPI),age-adjusted IPI,Follicular Lymphoma International Prognosis Index(FLIPI),and FLIPI2 to compare the efficacy of different treatment regimens and analyze the related prognostic factors.RESULTS The age of onset in patients ranged from 24 to 76 years,with a median age of 51 years.Most patients developed the disease at 40–59 years of age,and the male:female ratio was 1.6:1.No significant difference was noted in the curative effect between the non-chemotherapy,combined chemotherapy,and other chemotherapy regimens(P>0.05).Hemoglobin(Hb)level<120 g/L,Ki-67 value>50%,bone marrow involvement,and clinical stagesⅢ–IV were associated with a poor prognosis of FL(P<0.05).However,the influence of other indicators was not statistically significant.Risk grouping was performed using the FLIPI,and the results showed that 24.5%,40.8%,and 34.7%of patients were in the low-,moderate-,and high-risk groups,respectively.According to the survival analysis results,the survival rate of patients was lower in the high-risk group than in the other low-risk and moderate-risk groups(P<0.05).CONCLUSION FL mainly occurs in middle-aged and elderly men,primarily affecting lymph nodes and bone marrow.Hb level,Ki-67 value,bone marrow involvement,and clinical staging were used to evaluate prognosis.

Clinical Application of Double Ovulation Stimulation in Patients with Diminished Ovarian Reserve and Asynchronous Follicular Development Undergoing Assisted Reproduction Technology

Objective This study aimed to compare the clinical effects of double ovulation stimulation(DouStim)applied during the follicular and luteal phases with the antagonist protocol in patients with diminished ovarian reserve(DOR)and asynchronous follicular development undergoing assisted reproductive technology(ART).Methods The clinical data of patients with DOR and asynchronous follicular development receiving ART from January 2020 to December 2021 were retrospectively analyzed.The patients were divided into two groups according to their ovulation stimulation protocol:DouStim group(n=30)and antagonist group(n=62).Assisted reproduction and clinical pregnancy outcomes were compared between the two groups.Results In the DouStim group,the number of oocytes retrieved,metaphase II(MII)oocytes,two-pronuclei(2PN),day 3(D3)embryos,D3 high-quality embryos as well as blastocyst formation,implantation,and human chorionic gonadotropin-positive rates were significantly greater than those in the antagonist group(all P<0.05).No significant differences were found in MII,fertilization,or continued pregnancy rates at the first frozen embryo transfer(FET),in-vitro fertilization(IVF)cancellation,or early medical abortion rates between the groups(all P>0.05).Except for the early medical abortion rate,the DouStim group generally had favorable outcomes.In the DouStim group,the dosage and duration of gonadotropin and the fertilization rate were significantly greater in the first ovulation stimulation induction than in the second ovulation stimulation induction(P<0.05).Conclusion The DouStim protocol efficiently and economically obtained more mature oocytes and high-quality embryos for patients with DOR and asynchronous follicular development.

Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Follicular lymphoma(FL)is the most common low-grade lymphoma,and although nodal FL is highly responsive to treatment,the majority of patients relapse repeatedly,and the disease has been incurable with a poor prognosis.However,primary FL of the gastrointestinal tract has been increasingly detected in Japan,especially due to recent advances in small bowel endoscopy and increased opportunities for endoscopic examinations and endoscopic diagnosis.However,many cases are detected at an early stage,and the prognosis is good in many cases.In contrast,in Europe and the United States,gastrointestinal FL has long been considered to be present in 12%-24%of Stage-IV patients,and the number of advanced gastrointestinal cases is expected to increase.This editorial provides an overview of the recent therapeutic advances in nodal FL,including antibody-targeted therapy,bispecific antibody therapy,epigenetic modulation,and chimeric antigen receptor T-cell therapy,and reviews the latest therapeutic manuscripts published in the past year.Based on an understanding of the therapeutic advances in nodal FL,we also discuss future possibilities for gastroenterologists to treat gastrointestinal FL,especially in advanced cases.

Pediatric-type follicular lymphoma in a Crohn’s disease patient receiving anti-α4β7-integrin therapy:A case report

BACKGROUND Patients with autoimmune conditions receiving immunosuppressants are at risk of non-Hodgkin lymphomas(NHL).Vedolizumab(anti-α4β7-integrin antibody),a treatment-of-choice for Crohn’s disease(CD),reduces inflammatory lymphocyte trafficking into the intestinal mucosa.This effect is believed to be confined to the colon.CASE SUMMARY We report the case of a CD patient on vedolizumab for five years who developed pediatric-type follicular lymphoma.Work-up prior to therapy revealed a reduction in circulating T-lymphocytes and their suppressed response to mitogens.Rituximab,cyclophosphamide,vincristine,and prednisone chemoimmunotherapy resulted in durable lymphoma remission,and vedolizumab treatment was continued.While the patient’s T-lymphocyte population and immunoglobulin production recovered,the T-lymphocyte mitogen response remained suppressed.CONCLUSION This patient’s NHL may be linked to receiving anti-α4β7 therapy.Further research could be beneficial to determine if proactive surveillance for NHL and other systemic diseases is indicated in patients on vedolizumab.

Efficacy and safety of Revlimid combined with Rituximab in the treatment of follicular lymphoma: A meta-analysis

Objective:To evaluate the clinical efficacy and safety of lenalidomide combined with rituximab for treating follicular lymphoma.Methods:We searched PubMed,Web of Science,Cochrane Library,Embase,China Medical Biological Service system(CBM),VIP database(VIP),Wan fang database(Wan Fang Data),China Knowledge Network(CNKI),and ClinicTrails.gov for literature related to lenalidomide combined with rituximab for treating follicular lymphoma(until June 23,2022).The literature that met the requirements were screened out according to the established criteria,and the data were analyzed by RevMan5.4 and Stata14.0 to conduct a meta-analysis.Results:Eight studies involving 865 patients with follicular lymphoma were included.The results of the meta-analysis showed that the objective remission rate(RR=1.43,95%CI:1.26–1.61)and complete remission rate(RR=1.67,95%CI:1.27–2.21)of lenalidomide combined with rituximab for treating follicular lymphoma were significantly higher than those of rituximab alone.However,adverse reactions(neutropenia,diarrhea,nausea and vomiting,rash)were more likely to occur in the lenalidomide combined with the rituximab group,albeit at a low level.Conclusion:Compared to rituximab alone,lenalidomide combined with rituximab could significantly improve the objective and complete remission rates of patients with follicular lymphoma.However,as combination therapy may be associated with adverse reactions,timely corresponding measures should be taken during treatment.Therefore,to confirm the efficacy and safety of lenalidomide combined with rituximab for treating follicular lymphoma,it is necessary to conduct multicenter,multi-sample,randomized double-blind controlled trials,and single-arm trials.

Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas

Follicular lymphoma(FL)is the most common indolent B-cell lymphoma(BCL)globally.Recently,its incidence has increased in Europe,the United States,and Asia,with the number of gastrointestinal FL cases expected to increase.Genetic abnormalities related to t(14;18)translocation,BCL2 overexpression,NF-κB pathway-related factors,histone acetylases,and histone methyltransferases cause FL and enhance its proliferation.Meanwhile,microRNAs are commonly used in diagnosing FL and predicting patient prognosis.Many clinical trials on novel therapeutics targeting these genetic abnormalities and immunomodulatory mechanisms have been conducted,resulting in a marked improvement in therapeutic outcomes for FL.Although developing these innovative therapeutic agents targeting specific genetic mutations and immune pathways has provided hope for curative options,FL treatment has become more complex,requiring combinatorial therapeutic regimens.However,optimal treatment combinations have not yet been achieved,highlighting the importance of a complete understanding regarding the pathogenesis of gastrointestinal FL.Accordingly,this article reviews key research on the molecular pathogenesis of nodal FL and novel therapies targeting the causative genetic mutations.Moreover,the results of clinical trials are summarized,with a particular focus on treating nodal and gastrointestinal FLs.

子宫内膜异位症患者卵泡液外泌体miRNA谱差异及生信分析

目的探讨子宫内膜异位症(EMT)患者卵泡液来源的外泌体差异微小RNA(miRNA)对卵母细胞质量的影响。方法收集2021年12月—2022年3月在广州市第一人民医院生殖医学中心进行体外受精-胚胎移植/卵细胞浆内单精子注射助孕的20例不孕症患者的卵泡液,分为EMT组(EMT不孕症患者10例)和对照组(单纯男性因素不孕症患者10例)。采用高通量测序对卵泡液外泌体微小RNA(miRNA)谱进行分析,选出具有组间差异的miRNAs。结果与单纯男性因素不孕患者相比,EMT组有18个外泌体miRNAs差异有统计学意义,其中上调9个、下调9个。靶基因预测并采用GO和KEGG富集分析发现,这些靶基因主要参与磷脂酰肌醇-3-激酶/蛋白激酶B(PI3K-Akt)、核苷酸结合寡聚结构域NOD样受体、Ras等信号通路。结论EMT患者卵泡液来源的外泌体miRNA存在差异,差异的外泌体miRNAs可能通过多个信号通路影响EMT患者卵母细胞质量。

细胞程序性死亡调控动物卵泡闭锁的分子机制

卵泡闭锁是一个受高度受调控的复杂过程,与颗粒细胞的程序性死亡密切相关。细胞凋亡、自噬、铁死亡、坏死性凋亡和焦亡等独立或相互作用参与调控卵泡闭锁和影响卵巢功能,本文综述了这5种细胞程序性死亡方式调控动物卵泡闭锁的分子机制及相关影响因素,以期为减少颗粒细胞程序性死亡诱导的卵泡闭锁、提高畜禽的繁殖性能提供参考。

产蛋间隔前期鸽卵泡转录组比较分析揭示卵泡发育相关基因

旨在对产蛋间隔前期母鸽卵泡颗粒细胞(GC)层进行高通量测序,筛选出与鸽卵泡发育和选择相关的关键基因。本研究选择了80对12月龄产蛋规律、体重相近的白羽王鸽为研究对象,在产蛋间隔第1天(LI1)和第3天(LI3)分别选择3只母鸽,采集F1和SF1卵泡GC层,并利用RNA-seq进行转录组分析,筛选L1F1/L1SF1、L3F1/L3SF1、L1F1/L3F1和L1SF1/L3SF1组,4组间差异表达基因(DEGs),对DEGs进行GO功能注释和KEGG通路富集分析,通过STRING数据库进行蛋白质互作(PPI)网络分析并使用Cytoscape软件进行可视化处理筛选关键基因,各组随机选择5个DEGs进行RT-qPCR验证转录组的可靠性。在4组比对中分别获得77、2736、5698和3864个DEGs。GO分析显示,4组DEGs都主要富集的GO条目为细胞过程、细胞解剖实体和连接。KEGG通路富集分析显示,L1F1/L1SF1组和L3F1/L3SF1组DEGs均显著富集在类固醇激素生物合成和卵巢类固醇合成等信号通路,L1F1/L3F1组和L1SF1/L3SF1组DEGs均显著富集在糖胺聚糖降解、突触囊泡周期和氧化磷酸化等信号通路。进一步地,进行PPI网络分析并筛选与卵泡发育和选择密切相关的DEGs。各组随机选择5个DEGs进行RT-qPCR验证,表达趋势与测序结果一致。本研究利用RNA-seq技术筛选到与鸽卵泡发育和选择相关的关键基因——EEF2、DDX5、PLK2、IGF 2R、LHCGR、HSD 3B1、CYP 19A1和StAR,为进一步探究鸽卵泡发育和选择的分子调控机制提供了理论依据。

甲状腺滤泡性肿瘤的诊断研究进展

甲状腺滤泡状癌(FTC)不同于甲状腺滤泡性腺瘤,其特征为细胞的异型性以及包膜和血管浸润。由于肿瘤的良恶性只能通过术后病理鉴别,绝大部分滤泡性腺瘤患者采取诊断性腺叶切除,但接受腺叶切除的患者术后绝大部分为良性,因此目前亟须寻找一种针对FTC的额外诊断补充依据。术前评估肿瘤的良恶性可减少不必要的手术伤害和短期甚至长期的药物补充治疗。未来全面了解甲状腺滤泡性肿瘤的诊断进展,可以为疾病的治疗提供新思路。

西曲瑞克联合阿司匹林预防早发型卵巢过度刺激综合征的疗效观察

目的观察西曲瑞克联合阿司匹林预防早发型卵巢过度刺激综合征(OHSS)的疗效。方法回顾性收集2022年1月1日至7月1日于我院治疗的38例早发型OHSS患者资料,根据用药方案的不同分为对照组(19例)和干预组(19例)。取卵术后第1天,对照组患者给予阿司匹林肠溶片100 mg,口服至月经来潮;干预组患者给予注射用西曲瑞克0.25 mg,连续3 d皮下注射+阿司匹林肠溶片(用法用量同对照组)。观察并检测两组患者的首个黄体期、OHSS严重程度分级及取卵术后卵巢体积、腹水体积、血清雌二醇(E_(2))、白细胞计数(WBC)、红细胞比容(HCT)、中性粒细胞百分比(NEUT%)、D-二聚体(DD)、凝血酶原时间(PT)、纤维蛋白原(Fib)。结果干预组患者的首个黄体期显著短于对照组,中、重度患者比例显著低于对照组(P<0.05或P<0.01)。取卵术后,干预组患者的卵巢体积、腹水体积、血清E_(2)、WBC、NEUT%、HCT、DD、Fib总体低于对照组,PT显著高于对照组(P<0.05)。结论西曲瑞克联合阿司匹林预防早发型OHSS的疗效较单用阿司匹林更好。

年轻卵巢储备功能减退患者卵泡期与黄体期应用高孕激素状态超促排卵方案效果比较

目的:比较卵泡期和黄体期启动高孕激素状态超促排卵(PPOS)方案在35岁及以下卵巢储备功能减退(DOR)患者中的应用效果。方法:回顾性分析2018年6月至2021年12月在温州医科大学附属第一医院生殖医学中心采用PPOS方案行体外受精/卵胞质内单精子注射-胚胎移植的483例35岁及以下DOR患者的资料,其中采用卵泡期PPOS方案226例(FPPOS+CC组),黄体期PPOS方案257例(LPPOS+CC组)。比较两组的基线特征、超促排卵结果和实验室相关指标,并比较获得第三天(以下简称D3)优质胚胎的患者超促排卵后第一次冻融胚胎移植的妊娠结局。结果:两组间年龄、不孕年限、继发不孕占比、既往治疗周期数、体重指数、抗米勒管激素、窦状卵泡数、基础黄体生成素、基础孕酮水平、平均获卵数、MⅡ卵率、D3优质胚胎率、深度垂体抑制发生率、活产率和早产率等差异均无统计学意义(均P>0.05)。与FPPOS+CC组比较,LPPOS+CC组诱发排卵日黄体生成素(LH)水平[分别为4.0(2.7,5.3)和5.1(3.2,7.2)IU/L]、早发LH峰发生率(分别为3.13%和10.67%)、卵胞质内单精子注射双原核受精率(分别为72.16%和79.56%)均更低(P<0.05或P<0.01),而促性腺激素(Gn)天数[分别为11(9,12)和9(8,11)d]、Gn总量[分别为2213(1650,2700)和2000(1575,2325)IU]、诱发排卵日孕酮水平[分别为1.3(0.8,2.9)和0.9(0.6,1.2)ng/mL]、冻融胚胎移植的临床妊娠率(分别为61.88%和46.84%)和着床率(分别为42.20%和31.07%)均更高(均P<0.01)。结论:35岁及以下DOR患者采用LPPOS+CC方案后冻融胚胎移植临床妊娠结局更佳。

卵巢组织冻存与移植技术新进展

卵巢组织冻存与移植技术不仅保护女性生育力,还可保存卵巢内分泌功能,有效防治医源性早发性卵巢功能不全,尤其适用于青春期前女童与亟需原发病治疗的女性。卵巢组织冻存的有效性与安全性已得到了广泛验证,目前的临床金标准为慢速冻存,而玻璃化冻存仅适用于研究。尽管该技术近年来发展迅速,但仍面临超低温冻存损伤、冷冻保护剂毒性、卵泡储备量的评估、冻存与移植的安全性等问题。本文针对以上问题的研究进展进行综述。

早卵泡期长效长方案促排卵过程中内源性黄体生成素升高后拮抗剂的应用对临床结局的影响

目的:探讨早卵泡期长效长方案控制性促排卵过程中出现内源性黄体生成素(LH)升高后拮抗剂的应用对新鲜周期移植临床结局的影响。方法:回顾性分析2016年9月至2022年12月于河南省人民医院生殖医学中心行体外受精/卵胞浆内单精子注射-胚胎移植助孕的早卵泡期长效长方案出现内源性LH升高的240个周期,根据是否添加拮抗剂分为两组,并采用倾向性评分匹配进行1∶1匹配,最终纳入194个周期,其中A组(添加拮抗剂)97个周期,B组(未添加拮抗剂)97个周期。比较两组患者促排卵过程中相关临床指标及新鲜周期移植临床结局的差异。结果:A组Gn应用时间、Gn启动日LH、 hCG前日LH水平、成熟卵数均高于B组,但hCG日LH水平低于B组(P<0.05)。A、B组平均移植胚胎数、卵裂期胚胎移植占比、临床妊娠率、异位妊娠率及活产率差异无统计学意义(P>0.05)。结论:早卵泡期长效长方案控制性促排卵出现内源性LH升高时添加拮抗剂可以有效抑制LH水平,获得较为理想的临床结局。

三促汤联合绒促性素对FM/TE不孕症患者排卵率、妊娠率的影响及对临床疗效的探究

[目的]探究三促汤联合绒促性素对卵泡发育不良(FM)/薄型子宫内膜(TE)不孕症患者排卵率、妊娠率的影响及对临床的疗效。[方法]选取广西中医药大学附属瑞康医院2022年7—10月于门诊就诊的105例不孕症患者为研究对象,随机数字表法将105例患者分为35例中药组,35例西药组和35例试验组。中药组:促卵泡汤+促排卵汤+促黄体汤;西药组:克罗米芬(CC)+绒促性素(HCG)2 000 IU肌肉注射;试验组:(促卵泡汤+CC)+(促排卵汤+HCG 2 000 IU肌肉注射)+促黄体汤。以此检测各组患者排卵率、妊娠率、卵泡的最大直径、子宫内膜的厚度、血液流变学指标、卵泡刺激素(FSH)、促黄体生成素(LH)、雌二醇(E2)水平、中医证候评分、临床疗效的情况变化。[结果]与中药组、西药组比较,试验组患者排卵率、妊娠率、临床疗效升高,不良反应发生率较低(P<0.05)。与治疗前比较,治疗后各组患者卵泡的最大直径、子宫内膜的厚度、FSH、E2水平升高,血沉、全血低切黏度、血浆黏度、全血高切黏度、胸闷胀痛、月经不调、心烦不舒、易怒烦躁、小腹胀痛、乳房胀痛评分降低(P<0.05),与中药组、西药组治疗后比较,试验组患者治疗后卵泡的最大直径、子宫内膜的厚度、FSH、E2有所上升(P<0.05),治疗后试验组患者血沉、全血低切黏度、血浆黏度、全血高切黏度、胸闷胀痛、月经不调、心烦不舒、易怒烦躁、小腹胀痛、乳房胀痛评分及总积分降低(P<0.05),而LH表达差异无统计学意义(P>0.05)。[结论]通过使用三促汤联合HCG治疗,可有效改善患者妊娠率及排卵率,调节机体性激素及血液流变学相关指标水平,提高临床疗效。

肝脏滤泡树突状细胞肉瘤的MRI特征

目的:探讨肝脏滤泡树突状细胞肉瘤(FDCS)的MRI特征。方法:回顾性分析7例经手术及病理证实的肝脏FDCS的术前MRI表现特征。MRI图像分析包括观察病灶部位、大小、形态、边缘、病灶内囊变、出血、脂肪,平扫信号、强化方式和其他伴随征象,有无肝包膜回缩,邻近胆管有无扩张、肝门区及腹膜后有无淋巴结转移等征象。结果:7个病灶均为肝内单发类圆形或椭圆形病灶,边缘清晰光滑,肿瘤实性部分T1WI呈低信号,T2WI呈高信号,DWI呈高信号,ADC图实性部分呈低或稍低信号,2个病灶表现为信号均匀的实性肿块,5个病灶为实性肿块伴有不同程度的囊变,其中1个病灶囊变明显,并见出血。动态增强扫描5个病灶表现为“速升平台型”模式;2个病灶表现为“速升缓降型”模式;1个病灶周围异常灌注,2个病灶见延迟强化的包膜;1个病灶周围胆管轻度扩张,所有病例肝门区及腹膜后未见肿大淋巴结。结论:肝脏FDCS的MRI表现有一定的特征,多表现为边界清楚的肿块,常伴有不同程度囊变,实性部分信号均质,动脉期均呈明显强化,多数表现为明显持续强化。

慢性淋巴细胞白血病患者Tfh细胞及其亚群水平的变化和临床意义研究

目的 初步探讨Tfh细胞及其亚群在慢性淋巴细胞白血病(CLL)患者中的变化特点,并分析其临床意义。方法 选取2021年1月-2023年9月新疆医科大学第一附属医院收治的70例初诊CLL患者为CLL组,另选取该院体检健康人员50例为对照组。应用流式细胞术检测Tfh、Tfh1、Tfh2、Tfh17细胞比例,并分析Tfh细胞PD-1和ICOS的表达水平;实时荧光定量聚合酶链反应检测BCL-6、Blimp-1、IL-21基因表达;Western blotting检测BCL-6、Blimp-1蛋白表达;酶联免疫吸附试验检测血清细胞因子IL-21的水平。结果 CLL组外周血Tfh、Tfh1、PD-1+Tfh、ICOS+Tfh和PD-1+ICOS+Tfh细胞比例较对照组增加(P <0.05),亚群比值Tfh1/(Tfh2+Tfh17)比值也升高(P <0.05)。与对照组相比,CLL组BCL-6、Blimp-1、IL-21基因和蛋白相对表达量均升高(P <0.05),BCL-6/Blimp-1比值也升高(P <0.05)。Pearson相关性分析结果显示,BCL-6基因和蛋白表达、BCL-6/Blimp-1比值、IL-21水平与Tfh、Tfh1/(Tfh2+Tfh17)均呈正相关(P <0.05)。临床指标分析结果显示,随着IPI评分分组越靠后,Tfh细胞比例、Tfh1/(Tfh2+Tfh17)比值越高,并且与骨髓中B淋巴细胞呈正相关(P <0.05),与免疫球蛋白呈负相关(P <0.05)。结论 CLL患者外周血Tfh细胞参与疾病发病机制,并且Tfh细胞亚群存在偏向于Tfh1细胞的失衡,Tfh细胞的异常分化可能参与CLL的发病和体液免疫紊乱机制。